Introduction

37
The human gastrointestinal tract is colonized by hundreds of different microorganisms, 38 which together form the gut microbiota (1, 2). Use of antibiotics is one of the factors known to 39 alter the microbiota composition, which in turn may have an effect on an individual's health.
40
Typical adverse events associated with antibiotic use include various gastrointestinal symptoms 41 such as diarrhea, nausea, vomiting, and abdominal pain (3). Among them, antibiotic-associated 42 diarrhea (AAD), often defined as 'diarrhea that occurs in relation to antibiotic treatment with 43 the exclusion of other etiologies' (4), is the best documented.
44
Over 30 randomized controlled trials (RCTs), mostly with probiotics as an intervention, 45 have been performed to assess the prophylactic strategies for AAD in children (5). In the largest probiotics is the subject of a lasting discussion due to their cost, and the fact that AAD is usually 65 a mild and self-limiting disease (18) . To draw practical conclusions from RCTs, it is important 66 to assess AAD severity and its impact on the patient's everyday life, including global 67 assessment and health-related quality of life, with agreed-upon definitions and outcomes. 
Data extraction
120
The data from the included studies were extracted using an abstraction form developed Among the included studies, 32 (89%) were RCTs, and the remaining 4 were NRTs.
166
The total number of participants was 5506, ranging from 18 to 653 children in individual trials.
167
Ten trials were conducted in the inpatient setting, 14 in the outpatient setting, 5 in the mixed Tables S4 & S5 .
177
The RoB in the included trials varied. Most of the studies were characterized by 178 substantial RoB. A summary of the RoB assessment is presented in S1 Fig.   179 Outcome domain: diarrhea
180
The occurrence/incidence of diarrhea was reported as an outcome in 32 (89%) of the 181 included studies and 20 (63%) of these studies reported it as a primary outcome. In only 20
182
(63%) of these 32 studies were the criteria for diarrhea diagnosis clearly defined. In the 183 remaining studies, the occurrence of diarrhea was reported by parents or patients during 184 interviews or in study diaries, and diagnosed based on the participants' or investigators' 185 judgment, with unclear diagnostic criteria. In 9 (28%) of the studies which assessed this 186 outcome, various stool form scales were used, most commonly (7 studies) the Bristol Stool
187
Form Scale (BSFS) (55). 
241
In 2 studies, (7, 10), the GSRS was used to assess the gastrointestinal symptoms (56) .
242
Additionally, a visual analog scale for abdominal pain intensity was used in one study (51), and 243 a 3-point GI symptom rating scale was used in another (44). In the remaining studies, the 244 gastrointestinal symptoms were reported by parents and/or children during interviews or in 245 study diaries. antibiotic discontinuation due to diarrhea (6 studies), need for intravenous rehydration (5 255 studies), and need for hospitalization due to diarrhea (5 studies).
256
Only 2 studies assessed outcomes from "life impact" core area. A single study reported 257 data on absence from school/day care, missed parental days at work, and overall health (38),
258
and another study reported the data on duration of hospital stay (31). 
Discussion
261
In this review of outcomes used in studies assessing probiotic prophylactic interventions 262 during antibiotic therapy in children, 32 RCTs and 4 NRTs were included. The incidence
263
(occurrence) of diarrhea was the most commonly reported outcome. However, diagnostic 264 criteria for diarrhea were clearly defined in only 63% of the 32 studies reporting this outcome.
265
The majority of those studies did not utilize a validated instrument to assess the construct of performed the microbiological testing is much more likely to be an actual AAD.
321
The most commonly assessed outcome from the 'diarrhea' domain was incidence data. considered as a part of core outcomes(67).
340
The included studies also varied in the terms of follow-up duration with the majority of 341 the studies following patients during the entire duration of antibiotic therapy and for at least 342 one week after antibiotic cessation. Considering the usually short incubation time of AAD (68), 343 these lengths of follow-up should be sufficient to identify most of the cases. 
